AI assistant
PFIZER INC — Director's Dealing 2021
Mar 2, 2021
29831_dirs_2021-03-02_33ccc2b5-3618-40f0-9674-af86d275f434.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2021-02-27
Reporting Person: DAMELIO FRANK A (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-27 | Common Stock | M | 152785.0000 | $22.3500 | Acquired | 607441.0000 | Direct |
| 2021-02-27 | Common Stock | F | 27381.0000 | $33.4900 | Disposed | 580060.0000 | Direct |
| 2021-02-27 | Common Stock | F | 96872.0000 | $34.6400 | Disposed | 483188.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-27 | Stock Appreciation Rights | $22.3500 | M | 152785.0000 | Disposed | 2021-02-27 | Common Stock (152785.0000) | Direct |
Footnotes
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: Price is the closing price of Pfizer common stock on February 26, 2021.
F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.